(Q34607677)

3 August 2017

1 reference

title

Rifaximin pharmacology and clinical implications (English)

1 reference

3 August 2017

1 reference

7

Maurizio Gabrielli

1 reference

3 August 2017

Veronica Ojetti

1

1 reference

3 August 2017

Ernesto Cristiano Lauritano

2

1 reference

3 August 2017

Federico Barbaro

3

1 reference

3 August 2017

Alessio Migneco

4

1 reference

3 August 2017

Maria Elena Ainora

5

1 reference

3 August 2017

Luigi Fontana

6

1 reference

3 August 2017

Antonio Gasbarrini

8

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Drug Metabolism & Toxicology

3 August 2017

published in

1 reference

3 August 2017

volume

5

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

675-682

1 reference

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Rifaximin: a review of its use in the management of traveller's diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Recent trends in rifamycin research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Rifaximin: in vitro and in vivo antibacterial activity--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Drug excretion into breast milk--overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

21 January 2018

Travellers' diarrhoea

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Poorly absorbed antibiotics for the treatment of traveler's diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Travellers' diarrhoea: contemporary approaches to therapy and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Systematic review: prevention of travellers' diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Rifaximin for the treatment of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Small intestinal bacterial overgrowth recurrence after antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Gastrointestinal manifestations of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Enteric Microflora in IBD: Pathogens or Commensals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Mucosal flora in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

An open-label evaluation of rifaximin in the treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Management of inflammatory bowel disease: does rifaximin offer any promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Antibiotics for inflammatory bowel disease: do they work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Antimicrobials in the management of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Diverticular disease of the colon at a regional general hospital in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Review article: uncomplicated diverticular disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Interaction between rifaximin and dietary fibre in patients with diverticular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902973695

10.1517/17425250902973695

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference